Patients should have insured access to the necessary treatment for MGD

AND

Doctors should receive fair reimbursement for that treatment.

Today, we don’t have this. Which is why only 5% of patients get a heat and expression treatment1, when 86% may need it.2

We say that’s not right for anyone. Sight Sciences and the TearCare® System are boldly stepping forward to fight for equitable care.

Learn more about our vision to remove the barriers to MGD care.

Patients should have insured access to the necessary treatment for MGD, and doctors should receive fair reimbursement for that treatment.

Today, we don’t have this. Which is why only 5% of patients get a heat and expression treatment1, when 86% may need it.2

We say that’s not right for anyone. Sight Sciences and the TearCare® System are boldly stepping forward to fight for equitable care.

Learn more about the Tearcare® vision for Insured Access to MGD Care.

Learn more about our vision to remove the barriers to MGD care. Sign-up to request a call from a rep.

References:
  1. Market Scope 2021 Ocular Surface Disease Survey
  2. Lemp, M. A., Crews, L. A., Bron, A. J., Foulks, G. N., & Sullivan, B. D. (2012). Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea, 31(5), 472 -478. https://doi.org/10.1097/ICO.0b013e318225415a

Indications for Use: The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
The TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for Contraindications, Warnings, Precautions and Adverse Events.

SightSciences_TearCare_Logo
  • 4040 Campbell Ave, Suite 100
  • Menlo Park CA 94025
  • T: 877-266-1144

© 2022 Sight Sciences, Inc.      9/22     TC-2382-US.v2     TearCare® is a registered trademark of Sight Sciences.